W-SCOPE Corporation FY2027 Q2 Earnings Report

Quick View

Executive Summary

Revenue increased 32.9% year on year, while the operating loss and net loss narrowed from the previous year but remained in the red, resulting in higher revenue and reduced losses. Revenue was ¥1.93B (¥1.45B in the previous year, +32.9%), operating income was ¥-1.39B (¥-2.87B in the previous year), ordinary income was ¥-3.09B (¥-5.41B in the previous year), and net income was ¥-3.10B (¥-5.43B in the previous year). The structure in which cost of sales exceeds revenue continued, and the gross margin was -51.5% (improving from -165.5% in the previous year) and remained at a significantly negative level. The primary factors behind the improvement in earnings were revenue growth of more than 30% in both the Separator Business and Ion-Exchange Membrane Business, as well as a 15.6% reduction in SG&A expenses. However, non-operating expenses of ¥1.85B, including an equity-method investment loss of ¥1.69B, expanded the ordinary loss.

Factors Affecting Performance

【Revenue】Revenue was ¥1.93B, representing a 32.9% year-on-year increase. By segment, the Separator Business, which accounted for 58.7% of revenue, generated ¥1.13B (+33.5%), while the Ion-Exchange Membrane Business generated ¥0.80B (+32.0%), with both businesses posting growth at nearly the same rate.

【Profit and Loss】Gross profit was ¥-0.99B (¥-2.40B in the previous year), and operating income was ¥-1.39B (¥-2.87B in the previous year), with the loss narrowing. Segment profit (on a gross profit basis) remained significantly negative for the Separator Business at ¥-1.51B (gross margin of -133.9%), while the Ion-Exchange Membrane Business secured high profitability at ¥+0.52B (gross margin of 65.3%), with the profitability gap between the two businesses determining consolidated earnings. Of non-operating expenses of ¥1.85B, the equity-method investment loss accounted for ¥1.69B, expanding the ordinary loss to ¥-3.09B. Net income was ¥-3.10B, nearly the same level as the ordinary loss, with no significant divergence arising from extraordinary gains or losses. In conclusion, the company recorded higher revenue and a reduced loss.

Segment Analysis

The Separator Business generated revenue of ¥1.13B (+33.5% year on year) and a segment loss of ¥-1.51B (gross margin of -133.9%), remaining unprofitable despite higher revenue. The Ion-Exchange Membrane Business generated revenue of ¥0.80B (+32.0%) and segment profit of ¥+0.52B (gross margin of 65.3%), maintaining high profitability. The gross margin gap between the two businesses reached approximately 199pt, making improvement in the profitability of the Separator Business, which has the larger revenue mix, the key to consolidated earnings. It should be noted that segment profit is based on an adjustment to consolidated gross profit and therefore differs from operating income in its measurement basis.

Key Financial Indicators

【Profitability】The operating margin improved to -72.0% (from -197.8% in the previous year), and the net profit margin improved to -161.0% (from -374.4% in the previous year), but both remained at significantly negative levels. EBITDA was ¥-0.64B and the EBITDA margin was -33.1%; even after factoring in depreciation and amortization of ¥0.75B, the core business remained unable to generate positive cash flow.【Cash Flow Quality】Operating Cash Flow (OCF) of ¥0.37B had the opposite sign to the net loss of ¥3.10B, meaning that OCF/net income has no meaningful interpretive value. OCF was supported by depreciation and amortization, collection of trade receivables of ¥0.37B, and an increase in accounts payable of ¥0.17B, while inventory increased by ¥0.31B and absorbed cash.【Investment Efficiency】Annualized ROE was -15.8%, and total asset turnover was 0.078x, both low levels. Investment securities accounted for ¥34.00B (69.0%) of total assets of ¥49.28B, and this asset composition structurally depressed the turnover ratio.【Financial Soundness】Although the equity ratio was high at 79.8%, current assets of ¥2.96B compared with current liabilities of ¥7.76B resulted in a current ratio of approximately 38%. Most of the ¥7.03B in interest-bearing debt was concentrated in the short term, with short-term borrowings of ¥5.93B.

Cash Flow Analysis

OCF was an inflow of ¥0.37B, down 66.6% from ¥1.10B in the same period of the previous year, but the fact that the company secured positive OCF despite a net loss is noteworthy. The decrease in trade receivables of ¥0.37B and increase in accounts payable of ¥0.17B contributed positively, while the increase in inventories of ¥0.31B absorbed cash. Investing Cash Flow was an inflow of ¥0.40B, primarily due to the collection of short-term loans receivable of ¥0.35B and the sale of investment securities of ¥0.14B; capital expenditures amounted to only ¥0.17B. With capital expenditures of ¥0.17B against depreciation and amortization of ¥0.75B, CapEx/depreciation and amortization was a low 0.23x, suggesting a restrained approach to replacement investment. Financing Cash Flow was ¥-0.35B, primarily due to repayment of short-term borrowings. Free cash flow was positive at ¥0.76B, but this increase depended on the collection of investment and loan assets, warranting a cautious assessment of the company’s sustainable cash-generating capacity from core operations alone.

Earnings Quality

The reduction in losses during the period reflected an improvement in the recurring earnings structure due to higher revenue and a 15.6% reduction in SG&A expenses. At the same time, an equity-method investment loss of ¥1.69B, equivalent to 55% of the ordinary loss, was recorded as a non-operating expense and represents a factor distinct from the company’s business operations themselves. Non-operating income was small at ¥0.14B, primarily consisting of a foreign exchange gain of ¥0.04B, and its impact on earnings quality was limited. OCF of ¥0.37B diverged from the net loss of ¥3.10B; from an accrual perspective, working capital factors such as collection of trade receivables and an increase in accounts payable, as well as non-cash items such as depreciation and amortization, contributed to OCF. Comprehensive income was ¥-2.06B, exceeding the net loss of ¥3.10B, as foreign currency translation adjustments of ¥0.23B and the share of OCI of equity-method investees of ¥0.82B supported shareholders’ equity through other comprehensive income.

Earnings Forecast and Guidance

The full-year company plan calls for revenue of ¥6.00B, operating income of ¥-2.40B, and ordinary income of ¥-4.40B, with no revision to the earnings forecast. First-half revenue of ¥1.93B represented only 32.1% of the full-year plan, below the standard first-half progress rate of 50%. Meanwhile, first-half progress toward the planned net loss of ¥4.40B reached 70.5%, leaving allowable net losses of only approximately ¥1.29B in the second half. To achieve the plan, the company must record revenue of ¥4.07B in the second half, approximately 2.1 times the first-half level. Improvement in the profitability of the Separator Business and containment of equity-method investment losses will be key to progress toward the plan.

Shareholder Returns

Both the Q2 dividend and full-year dividend forecast are ¥0 per share, and the company continues to pay no dividends. Given the financial position, including an interim net loss of ¥3.10B, retained earnings of ¥-31.26B, and a current ratio of approximately 38%, securing working capital and refinancing short-term borrowings currently take priority over capital returns.

Risk Factors

1. Risk of deteriorating profitability in the Separator Business: The Separator Business accounts for 58.7% of revenue but recorded a segment loss of ¥-1.51B against revenue of ¥1.13B (gross margin of -133.9%). Fluctuations in capacity utilization and yield could have a significant impact on consolidated earnings.

2. Short-term liquidity risk: The current ratio is approximately 38%, with cash of ¥0.68B compared with current liabilities of ¥7.76B. Short-term borrowings account for 84.3% of interest-bearing debt of ¥7.03B, and changes in refinancing conditions could directly affect liquidity.

3. Risk of fluctuations in equity-method investment losses: The equity-method investment loss of ¥1.69B accounts for 55% of the ordinary loss of ¥3.09B. Investment securities of ¥34.00B account for 69.0% of total assets, and fluctuations in the performance of investees could significantly affect consolidated earnings and shareholders’ equity.

Industry Benchmark (For Reference; Company Analysis)

Profitability and Returns

Profitability was significantly below the industry median and markedly inferior to the manufacturing industry average.

Growth and Capital Efficiency

The revenue growth rate was substantially above the industry median, placing the company in a favorable position within the industry in terms of revenue growth.

※Source: Company compilation

Key Points from the Financial Results

1. Revenue and operating earnings improved from the previous year, but with a gross margin of -51.5% and an EBITDA margin of -33.1%, the earnings structure has not yet normalized. The profitability gap between the Ion-Exchange Membrane Business (gross margin of 65.3%) and the Separator Business (same: -133.9%) determines consolidated earnings.

2. Although the capital structure is strong, with an equity ratio of 79.8%, short-term liquidity is weak, with a current ratio of approximately 38% and a short-term debt ratio of 84.3%. Accordingly, short-term liquidity trends require monitoring separately from the strength of the capital base.

3. While revenue progress against the full-year plan was only 32.1%, net loss progress had reached 70.5% of the plan, making the simultaneous achievement of sharp revenue growth and loss reduction in the second half a prerequisite for meeting the plan.

Theoretical Share Price (Reference Value)

Sensitivity: ¥312–¥329 at cost of equity ±1%; ¥312–¥326 at ω±0.1.

Notes:

• Since forecast ROE is below the cost of equity, the theoretical value is below book value per share.
• Net assets as of the quarter-end are used (there is a timing difference from the full-year forecast).
• Since net assets include non-controlling interests, the theoretical value may be calculated somewhat higher.

(Calculation model: Residual income model (Ohlson-type; explicit 5-year fade) / Interest rate reference month: 2026-08 / Mechanically calculated value based solely on publicly disclosed data; this is not a forecast of the market share price or a recommendation of any specific investment action, and does not forecast or guarantee future share prices.)

---

This report is an earnings analysis document automatically generated by AI through analysis of XBRL earnings summary data. It does not recommend investment in any specific security. Industry benchmarks are reference information compiled by the company based on publicly disclosed earnings data. Investment decisions should be made at your own discretion and responsibility, after consulting with professionals as necessary.

---End of Report---